(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 December 2015 (03.12.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/181637 A1

(51) International Patent Classification:
A61K 31/538 (2006.01) *A61P 31/04* (2006.01)

(21) International Application Number:
PCT/IB2015/001585

(22) International Filing Date:
27 May 2015 (27.05.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/004,246 29 May 2014 (29.05.2014) US

(71) Applicant: **ENTASIS THERAPEUTICS LIMITED** [GB/GB]; 2 Kingdom Street, London W2 6BD (GB).

(72) Inventor: **HUBAND, Michael**; Astrazeneca R&d Boston, 35 Gatehouse Drive, Waltham, MA 02451 (US).

(74) Agent: **STEVENS, Ian E.**; Potter Clarkson LLP, The Belgrave Centre, Talbot Street, Nottingham NG1 5GG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2015/181637 A1

(54) Title: FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

(57) Abstract: Disclosed are methods for treating various bacterial infections with (2*R*,4*S*,4a*S*)-11-fluoro-2,4-dimethyl-8-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4a-tetrahydro-2'*H*,6*H*-spiro[1,4-oxazino[4,3-a][1,2]oxazolo[4,5-*g*]quinoline-5,5'-pyrimidine]-2',4',6' (1'*H*,3'*H*)-trione, or a pharmaceutically acceptable salt thereof.